PortalPublikationenLocally advanced esophageal carcinoma: is there still a role...

Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?

Standard

Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? / Reeh, Matthias; Nentwich, Michael F; Asani, Samir; Uzunoglu, Faik G; Bockhorn, Maximilian; Sauter, Guido; Rösch, Thomas; Izbicki, Jakob R; Bogoevski, Dean.

in: J GASTROINTEST SURG, Jahrgang 19, Nr. 4, 01.04.2015, S. 587-93.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reeh, M, Nentwich, MF, Asani, S, Uzunoglu, FG, Bockhorn, M, Sauter, G, Rösch, T, Izbicki, JR & Bogoevski, D 2015, 'Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?', J GASTROINTEST SURG, Jg. 19, Nr. 4, S. 587-93. https://doi.org/10.1007/s11605-015-2762-y

APA

Reeh, M., Nentwich, M. F., Asani, S., Uzunoglu, F. G., Bockhorn, M., Sauter, G., Rösch, T., Izbicki, J. R., & Bogoevski, D. (2015). Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? J GASTROINTEST SURG, 19(4), 587-93. https://doi.org/10.1007/s11605-015-2762-y

Vancouver

Reeh M, Nentwich MF, Asani S, Uzunoglu FG, Bockhorn M, Sauter G et al. Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? J GASTROINTEST SURG. 2015 Apr 1;19(4):587-93. https://doi.org/10.1007/s11605-015-2762-y

Bibtex

@article{c8aa9b2c944b45b7b99018caf7b716b9,
title = "Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?",
abstract = "OBJECTIVE: The aim of this study is to evaluate the impact of upfront surgery without neoadjuvant pretreatment on survival in patients with clinically staged locally advanced esophageal carcinoma before the new era of neoadjuvant therapy regimes.MATERIAL AND METHODS: This is a retrospective analysis of prospectively collected data of patients with clinically advanced esophageal cancer (cT3) and without neoadjuvant treatment who underwent transthoracic esophagectomy (TTE) in curative intent between 1992 and 2009. Locally advanced esophageal cancer was defined based on presurgical computertomography, endoscopy, and endosonography findings as a tumor infiltrating the paraesophageal tissue or the adjacent structures, with or without lymph node affection.RESULTS: Histological subtypes included 131 squamous cell carcinomas (SCC) and 81 adenocarcinomas (AC). Complete resection (R0) was achieved in 84.0 % of all 212 patients. Thirty-day mortality rate was 7.1 %. Final pathology revealed 50 patients (23.5 %) with pT1 or pT2 carcinomas which were preoperatively overstaged. Median overall survival following TTE for SCC was 13.7 months (95 % CI; 10.1-17.2 months) and 24.8 months (95 % CI; 14.5-35.1 months) for AC, respectively (p = 0.007). The 5-year survival rates were 14 % for SCC and 26 % for AC, respectively. In median, 27 lymph nodes were resected. On multivariable analyses, histological type, tumor localization, tumor grading, and resection status remained independent factors influencing overall survival.CONCLUSION: Our results in the treatment of patients with locally advanced esophageal carcinoma undergoing primary TTE are comparable to the results reported for patients undergoing neoadjuvant chemo-radio-therapy followed by surgery in the pre-CROSS-study era. Histological subtypes show different survival rates and should therefore be separately examined in future trials.",
author = "Matthias Reeh and Nentwich, {Michael F} and Samir Asani and Uzunoglu, {Faik G} and Maximilian Bockhorn and Guido Sauter and Thomas R{\"o}sch and Izbicki, {Jakob R} and Dean Bogoevski",
year = "2015",
month = apr,
day = "1",
doi = "10.1007/s11605-015-2762-y",
language = "English",
volume = "19",
pages = "587--93",
journal = "J GASTROINTEST SURG",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

RIS

TY - JOUR

T1 - Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?

AU - Reeh, Matthias

AU - Nentwich, Michael F

AU - Asani, Samir

AU - Uzunoglu, Faik G

AU - Bockhorn, Maximilian

AU - Sauter, Guido

AU - Rösch, Thomas

AU - Izbicki, Jakob R

AU - Bogoevski, Dean

PY - 2015/4/1

Y1 - 2015/4/1

N2 - OBJECTIVE: The aim of this study is to evaluate the impact of upfront surgery without neoadjuvant pretreatment on survival in patients with clinically staged locally advanced esophageal carcinoma before the new era of neoadjuvant therapy regimes.MATERIAL AND METHODS: This is a retrospective analysis of prospectively collected data of patients with clinically advanced esophageal cancer (cT3) and without neoadjuvant treatment who underwent transthoracic esophagectomy (TTE) in curative intent between 1992 and 2009. Locally advanced esophageal cancer was defined based on presurgical computertomography, endoscopy, and endosonography findings as a tumor infiltrating the paraesophageal tissue or the adjacent structures, with or without lymph node affection.RESULTS: Histological subtypes included 131 squamous cell carcinomas (SCC) and 81 adenocarcinomas (AC). Complete resection (R0) was achieved in 84.0 % of all 212 patients. Thirty-day mortality rate was 7.1 %. Final pathology revealed 50 patients (23.5 %) with pT1 or pT2 carcinomas which were preoperatively overstaged. Median overall survival following TTE for SCC was 13.7 months (95 % CI; 10.1-17.2 months) and 24.8 months (95 % CI; 14.5-35.1 months) for AC, respectively (p = 0.007). The 5-year survival rates were 14 % for SCC and 26 % for AC, respectively. In median, 27 lymph nodes were resected. On multivariable analyses, histological type, tumor localization, tumor grading, and resection status remained independent factors influencing overall survival.CONCLUSION: Our results in the treatment of patients with locally advanced esophageal carcinoma undergoing primary TTE are comparable to the results reported for patients undergoing neoadjuvant chemo-radio-therapy followed by surgery in the pre-CROSS-study era. Histological subtypes show different survival rates and should therefore be separately examined in future trials.

AB - OBJECTIVE: The aim of this study is to evaluate the impact of upfront surgery without neoadjuvant pretreatment on survival in patients with clinically staged locally advanced esophageal carcinoma before the new era of neoadjuvant therapy regimes.MATERIAL AND METHODS: This is a retrospective analysis of prospectively collected data of patients with clinically advanced esophageal cancer (cT3) and without neoadjuvant treatment who underwent transthoracic esophagectomy (TTE) in curative intent between 1992 and 2009. Locally advanced esophageal cancer was defined based on presurgical computertomography, endoscopy, and endosonography findings as a tumor infiltrating the paraesophageal tissue or the adjacent structures, with or without lymph node affection.RESULTS: Histological subtypes included 131 squamous cell carcinomas (SCC) and 81 adenocarcinomas (AC). Complete resection (R0) was achieved in 84.0 % of all 212 patients. Thirty-day mortality rate was 7.1 %. Final pathology revealed 50 patients (23.5 %) with pT1 or pT2 carcinomas which were preoperatively overstaged. Median overall survival following TTE for SCC was 13.7 months (95 % CI; 10.1-17.2 months) and 24.8 months (95 % CI; 14.5-35.1 months) for AC, respectively (p = 0.007). The 5-year survival rates were 14 % for SCC and 26 % for AC, respectively. In median, 27 lymph nodes were resected. On multivariable analyses, histological type, tumor localization, tumor grading, and resection status remained independent factors influencing overall survival.CONCLUSION: Our results in the treatment of patients with locally advanced esophageal carcinoma undergoing primary TTE are comparable to the results reported for patients undergoing neoadjuvant chemo-radio-therapy followed by surgery in the pre-CROSS-study era. Histological subtypes show different survival rates and should therefore be separately examined in future trials.

U2 - 10.1007/s11605-015-2762-y

DO - 10.1007/s11605-015-2762-y

M3 - SCORING: Journal article

C2 - 25652343

VL - 19

SP - 587

EP - 593

JO - J GASTROINTEST SURG

JF - J GASTROINTEST SURG

SN - 1091-255X

IS - 4

ER -